A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex

Mol Cancer Ther. 2006 Feb;5(2):287-95. doi: 10.1158/1535-7163.MCT-05-0456.

Abstract

We show that five topoisomerase I inhibitors (two indenoisoquinolines, two camptothecins, and one indolocarbazole) each intercalate between the base pairs flanking the cleavage site generated during the topoisomerase I catalytic cycle and are further stabilized by a network of hydrogen bonds with topoisomerase I. The interfacial inhibition paradigm described for topoisomerase I inhibitors can be generalized to a variety of natural products that trap macromolecular complexes as they undergo catalytic conformational changes that create hotspots for drug binding. Stabilization of such conformational states results in uncompetitive inhibition and exemplifies the relevance of screening for ligands and drugs that stabilize ("trap") these macromolecular complexes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Camptothecin / chemistry
  • Camptothecin / pharmacology
  • Crystallography
  • DNA / chemistry
  • DNA Damage
  • DNA Topoisomerases, Type I / chemistry
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Hydrogen Bonding
  • Indenes / chemistry*
  • Indenes / pharmacology*
  • Isoquinolines / chemistry*
  • Isoquinolines / pharmacology*
  • Molecular Structure
  • Topoisomerase I Inhibitors*
  • Topotecan / chemistry
  • Topotecan / pharmacology

Substances

  • Enzyme Inhibitors
  • Indenes
  • Isoquinolines
  • Topoisomerase I Inhibitors
  • norindenoisoquinoline
  • Topotecan
  • DNA
  • DNA Topoisomerases, Type I
  • Camptothecin